Decreased Sialic Acid Content of Plasma von Willebrand Factor in Precapillary Pulmonary Hypertension

Antonio Augusto Lopes; Bruno Ferraz de Souza; Nair Yukie Maeda

doi:10.1055/s-0037-1613892

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2000; 83(05): 683-687
DOI: 10.1055/s-0037-1613892

Review Article

Schattauer GmbH

Decreased Sialic Acid Content of Plasma von Willebrand Factor in Precapillary Pulmonary Hypertension

Authors

Antonio Augusto Lopes

^*From the Heart Institute, School of Medicine of the University of São Paulo, and Pró-Sangue Foundation, São Paulo, Brazil
Bruno Ferraz de Souza

^*From the Heart Institute, School of Medicine of the University of São Paulo, and Pró-Sangue Foundation, São Paulo, Brazil
Nair Yukie Maeda

^*From the Heart Institute, School of Medicine of the University of São Paulo, and Pró-Sangue Foundation, São Paulo, Brazil

Abstract

Summary

In pulmonary hypertension, defective von Willebrand factor protein (vWF) lacking large multimers is present in circulation. This is associated with evidence of chronic endogenous platelet activation. Since asialo vWF has been shown to promote platelet activation and aggregation, we decided to investigate possible changes in the sialic acid content of plasma vWF in patients with precapillary pulmonary hypertension. vWF-associated sialic acid was measured indirectly as a wheat germ agglutinin-reactive substance (WGA-RS, Western blotting), and directly, as a thiobarbituric acid-reactive substance (TBA-RS, spectrophotometric reading). In the sixteen patients we studied (ages 8–45 yr), circulating vWF concentration was 2.18 times normal (p <0.001). However, patient vWF subunit contained 19% (WGA-RS) to 24% (TBA-RS) less sialic acid than the normal protein (p <0.05 for both determinations). In five patients, vWF-associated sialic acid was below 50% normal. We conclude that circulating vWF is hyposialylated in precapillary pulmonary hypertension and speculate that this might influence its interaction with platelets in vivo in these patients.

Key words

Sialic acid - von Willebrand factor - pulmonary hypertension

Full Text

References

References
1 Osawa T, Tsuji T. Fractionation and structural assessment of oligosaccharides and glycopeptides by use of immobilized lectins. Ann Rev Biochem 1987; 56: 21-42.
2 Gahmberg CG, Tolvanen M. Why mammalian cell surface proteins are glycoproteins. Trends Biochem Sci 1996; 21: 308-11.
3 Aminoff D. The role of sialoglycoconjugates in the aging and sequestration of red cells from circulation. Blood Cells 1988; 14: 229-47.
4 Kotzé HF, van Wyk V, Badenhorst PN, Heyns AP, Roodt JP, Lötter MG. Influence of platelet membrane sialic acid and platelet-associated IgG on ageing and sequestration of blood platelets in baboons. Thromb Haemost 1993; 70 (04) 676-80.
5 Chopek MW, Girma J-P, Fujikawa K, Davie EW, Titani K. Human von Willebrand factor: A multivalent protein composed of identical subunits. Biochemistry 1986; 25: 3146-55.
6 Titani K, Kumar S, Takio K, Ericsson LH, Wade RD, Ashida K, Walsh KA, Chopek MW, Sadler JE, Fujikawa K. Amino acid sequence of human von Willebrand factor. Biochemistry 1986; 25: 3171-84.
7 Bastida E, Monteagudo J, Ordinas A, De Marco L, Castillo R. Asialo von Willebrand factor enhances platelet adhesion to vessel subendothelium. Thromb Haemost 1988; 60: 30-4.
8 Berkowitz SD, Federici AB. Sialic acid prevents loss of large von Willebrand factor multimers by protecting against amino-terminal proteolytic cleavage. Blood 1988; 72 (05) 1790-6.
9 Federici AB, De Romeuf C, De Groot PG, Samor B, Lombardi R, D’Alessio P, Mazurier C, Mannucci PM, Sixma JJ. Adhesive properties of the carbohydrate-modified von Willebrand factor (CHO-vWF). Blood 1988; 71 (04) 947-52.
10 Rabinovitch M, Andrew M, Thom H, Trusler GA, Williams WG, Rowe RD, Olley PM. Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects. Circulation 1987; 76: 1043-52.
11 Lopes AAB, Maeda NY, Aiello VD, Ebaid M, Bydlowski SP. Abnormal multimeric and oligomeric composition is associated with enhanced endothelial expression of von Willebrand factor in pulmonary hypertension. Chest 1993; 104: 1455-60.
12 Gralnick HR, Williams SB, McKeown LP, Rick ME, Maisonneuve P, Jenneau C, Sultan Y. von Willebrand’s disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor. J Clin Invest 1985; 76 (04) 1522-9.
13 Maeda NY, Bydlowski SP, Lopes AAB. Sialic acid content of von Willebrand factor subunit. A simple method for quantitative estimation. Clin Chim Acta 1998; 273: 209-11.
14 Aminoff D. Methods for the quantitative estimation of N-acetylneuraminic acid and their application to hydrolysates of sialomucoides. Biochem J 1961; 81: 384-92.
15 Debeire P, Montreuil J, Samor B, Mazurier C, Goudemand M, van Halbeek H, Vliegenthart JF. Structure determination of the major asparagine-linked sugar chain of human factor VIII-von Willebrand factor. FEBS Lett 1983; 151 (01) 22-6.
16 Samor B, Michalski JC, Mazurier C, Goudemand M, De Waard P, Vliegenthart JF, Strecker G, Montreuil J. Primary structure of the major O-glycosidically linked carbohydrate unit of human von Willebrand factor. Glycoconj J 1989; 06 (03) 263-70.
17 Matsui T, Kihara C, Fujimura Y, Mizuochi T, Titani K. Carbohydrate analysis of human von Willebrand factor with horseradish peroxidase-conjugated lectins. Biochem Biophys Res Commun 1991; 178 (03) 1253-9.
18 Rostagno C, Boddi PM, Poggesi L. Evidence for local platelet activation in pulmonary vessels in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease. Eur Respir J 1991; 04: 147-51.
19 Lopes AAB, Maeda NY, Almeida A, Jaeger R, Ebaid M, Chamone DAF. Circulating platelet aggregates indicative of in vivo platelet activation in pulmonary hypertension. Angiology 1993; 44: 701-6.
20 Lopes AAB, Maeda NY, Ebaid M, Chamone DAF, Pileggi F. Effect of intentional hemodilution on platelet survival in secondary pulmonary hypertension. Chest 1989; 95: 1207-10.
21 De Marco L, Girolami A, Russell S, Ruggeri ZM. Interaction of asialo von Willebrand factor with glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and mediates platelet aggregation. J Clin Invest 1985; 75 (04) 1198-203.
22 Goudemand J, Mazurier C, Samor B, Bouquelet S, Montreuil J, Goudemand M. Effect of carbohydrate modifications of factor VIII/von Willebrand factor on binding to platelets. Thromb Haemost 1985; 53 (03) 390-5.
23 Räbinä J, Pikkarainen M, Miyasaka M, Renkonen R. A time-resolved immunofluorometric assay of sialyl Lewis x-degrading α2,3-sialidase activity. Anal Biochem 1998; 258: 362-8.
24 van der Spoel A, Bonten E, d’Azzo A. Transport of human lysosomal neuraminidase to mature lysosomes requires protective protein/cathepsin A. EMBO J 1998; 17 (06) 1588-97.
25 Crestani B, Dehoux M, Seta N, Cuer M, Aubier M. Cell surface carbohydrates of rat alveolar type II cells in primary culture. Am J Respir Cell Mol Biol 1993; 08: 145-52.
26 Guthridge JM, Kaplan AM, Cohen DA. Regulation of B cell: T cell interactions: potential involvement of an endogenous B cell sialidase. Immunol Invest 1994; 23 (6-7): 393-411.
27 Hanson VA, Shettigar UR, Loungani RR, Nadijcka MD. Plasma sialidase activity in acute myocardial infarction. Am Heart J 1987; 114: 59-63.
28 Lopes AAB, Maeda NY. Abnormal degradation of von Willebrand factor main subunit in pulmonary hypertension. Eur Resp J 1995; 08: 530-6.